CLARUS THERAPEUTICS HOLDINGS (CRXT)

Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE...

Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news on Tuesday morning.

Why Is Pinduoduo (PDD) Stock Up 18% Today?

Pinduoduo (PDD) stock is getting a boost on Monday after the Chinese agriculture tech company released results for Q2 2022.

Dear AMC Stock Fans, Mark Your Calendars for Sept. 3

Fans of AMC Entertainment (AMC) stock will want to keep an eye on the company come Sept. 3 as it prepares for a special theater event.

Why Is Humanigen (HGEN) Stock Down 16% Today?

Humanigen (HGEN) stock is heading lower on Monday as investors react to a minimum price delisting notice from the Nasdaq Exchange.

Clarus Therapeutics (CRXT) Stock Plunges Ahead of Aug. 31 Delisting

Clarus Therapeutics (CRXT) stock is falling hard on Monday as investors prepare for the stock to be delisted later this week.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're breaking down the biggest pre-market stock movers and the news that has them rising and falling for Monday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday and what's moving them!

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23%...

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain...

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

Comparing Cardano Versus Clarus Therapeutics Hldgs Reveals New Low

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...